Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a report published on Tuesday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the stock. Mizuho lowered shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $140.00 to $132.00 in a report on Monday, February 24th. Piper Sandler reiterated a “neutral” rating and issued a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $132.00 target price on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. Eleven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $109.70.

Intra-Cellular Therapies Stock Performance

ITCI opened at $131.87 on Tuesday. The firm has a market capitalization of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies has a twelve month low of $64.09 and a twelve month high of $131.98. The firm’s 50-day moving average price is $131.29 and its 200 day moving average price is $109.06.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. As a group, analysts predict that Intra-Cellular Therapies will post -0.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Intra-Cellular Therapies

Large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. increased its stake in Intra-Cellular Therapies by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock worth $1,878,000 after buying an additional 2,157 shares during the period. Barclays PLC increased its stake in Intra-Cellular Therapies by 282.0% during the 3rd quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock worth $2,521,000 after buying an additional 25,435 shares during the period. Oak Ridge Investments LLC increased its stake in Intra-Cellular Therapies by 74.1% during the 4th quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock worth $1,656,000 after buying an additional 8,440 shares during the period. Principal Financial Group Inc. increased its stake in Intra-Cellular Therapies by 3.3% during the 3rd quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company’s stock worth $43,735,000 after buying an additional 18,865 shares during the period. Finally, Merit Financial Group LLC purchased a new stake in Intra-Cellular Therapies during the 4th quarter worth approximately $206,000. 92.33% of the stock is owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.